DK1592971T3 - Fremgangsmåde til in vitro-bedømmelse af udviklingsstatus for en infektion med et HIV-virus i et individ - Google Patents

Fremgangsmåde til in vitro-bedømmelse af udviklingsstatus for en infektion med et HIV-virus i et individ

Info

Publication number
DK1592971T3
DK1592971T3 DK04708764.8T DK04708764T DK1592971T3 DK 1592971 T3 DK1592971 T3 DK 1592971T3 DK 04708764 T DK04708764 T DK 04708764T DK 1592971 T3 DK1592971 T3 DK 1592971T3
Authority
DK
Denmark
Prior art keywords
infection
individual
hiv virus
vitro assessment
developmental status
Prior art date
Application number
DK04708764.8T
Other languages
English (en)
Inventor
Patrice Debre
Vincent Vieillard
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1592971T3 publication Critical patent/DK1592971T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
    • G01N2015/1472—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle with colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04708764.8T 2003-02-06 2004-02-06 Fremgangsmåde til in vitro-bedømmelse af udviklingsstatus for en infektion med et HIV-virus i et individ DK1592971T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290303A EP1445614A1 (en) 2003-02-06 2003-02-06 A method for the in vitro assessment of the progression status of an HIV virus in an invidual
PCT/EP2004/001106 WO2004070385A1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual

Publications (1)

Publication Number Publication Date
DK1592971T3 true DK1592971T3 (da) 2013-11-11

Family

ID=32605441

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04708764.8T DK1592971T3 (da) 2003-02-06 2004-02-06 Fremgangsmåde til in vitro-bedømmelse af udviklingsstatus for en infektion med et HIV-virus i et individ

Country Status (8)

Country Link
US (3) US20060257318A1 (da)
EP (3) EP1445614A1 (da)
CN (1) CN1777810A (da)
CA (1) CA2519012C (da)
DK (1) DK1592971T3 (da)
ES (1) ES2435040T3 (da)
SI (1) SI1592971T1 (da)
WO (1) WO2004070385A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method
ES2528109T3 (es) * 2012-05-31 2015-02-04 Innavirvax Compuestos inmunogénicos que comprenden péptido gp41 de VIH acoplado a proteína portadora CRM197
WO2016181292A1 (en) 2015-05-12 2016-11-17 Piramal Enterprises Limited A process for the preparation of verapamil hydrochloride
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
CN115350181B (zh) * 2022-08-17 2023-12-29 吉林大学 一种小分子化合物在制备抗病毒感染的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401663A (en) 1981-06-30 1983-08-30 The Procter & Gamble Company Novel sulfonamide derivatives
US4443473A (en) 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE355300T1 (de) * 1996-11-06 2006-03-15 Genentech Inc Gespannte, helixformende peptide und verfahren um sie herzustellen
WO1998030190A2 (en) 1997-01-13 1998-07-16 Sloan-Kettering Institute For Cancer Research Colon cancer kh-1 and n3 antigens
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
DK1240326T3 (da) * 1999-11-15 2009-06-02 Innate Pharma Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
WO2001055320A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
EP1328630A2 (en) * 2000-04-14 2003-07-23 Incyte Genomics, Inc. Secreted proteins
IL137419A0 (en) * 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
DK1368478T3 (da) 2001-01-05 2006-08-28 Sanofi Pasteur Polypeptid, der fremkalder HIV-neutraliserende antistoffer
WO2004016732A2 (en) * 2002-04-29 2004-02-26 The Trustees Of Columbia University In The City Of New York Astrocyte modulated genes and uses thereof

Also Published As

Publication number Publication date
EP1445614A1 (en) 2004-08-11
US8372955B2 (en) 2013-02-12
US20060257318A1 (en) 2006-11-16
EP1592971A1 (en) 2005-11-09
EP2207034B1 (en) 2015-04-15
CA2519012C (en) 2018-10-23
EP2207034A1 (en) 2010-07-14
CA2519012A1 (en) 2004-08-19
WO2004070385A1 (en) 2004-08-19
US20090117110A1 (en) 2009-05-07
ES2435040T3 (es) 2013-12-18
SI1592971T1 (sl) 2013-12-31
US20090136533A1 (en) 2009-05-28
EP1592971B1 (en) 2013-08-14
CN1777810A (zh) 2006-05-24

Similar Documents

Publication Publication Date Title
DK1992697T3 (da) Fremstilling af TNFR-Fc
DE60329367D1 (de) Verwendung bei der bekämpfung von hepatitis c virusinfektion
DK1732604T3 (da) Fremgangsmåder til behandling af hiv-infektion
IS8476A (is) Lifrarbólgu C-veirutálmar
ATE382348T1 (de) Hepatitis c virus polymerase inhibitoren mit heterobicylische struktur
DK1653807T3 (da) Anvendelse af dermale mikroorganer
IS7530A (is) Lifrarbólgu C-veirutálmar
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1831357T3 (da) Genvinding af influenzavirus
DK1622880T3 (da) Substituerede dihydroquinazoliner med antivirale egenskaber
ITFI20030043A1 (it) Velivolo biplano ad ali contrapposte ad elevata stabilita' statica
DK1881848T3 (da) Forebyggelse af hiv-infektion med tmc278
DK1673106T3 (da) Optimeret ekspression af HPV 45 L1 i gær
DE602005015295D1 (de) Lasersystem mit ultrakurzen laserimpulsen
DK1981506T3 (da) Langtidsbehandling af HIV-infektion med TMC278
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1744781T3 (da) Behandling af infektionssygdomme
DK1709075T3 (da) Behandling af virusinfektioner
DK1694694T3 (da) Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1333906T3 (da) Anvendelse af polymerisater som filterhjælpe- og/eller stabiliseringsmidler
DE60220625D1 (de) Verbesserungen an Turbomaschineninjektoren
DK1592971T3 (da) Fremgangsmåde til in vitro-bedømmelse af udviklingsstatus for en infektion med et HIV-virus i et individ